
KI-7
CAS No. 1489263-00-4
KI-7 ( —— )
产品货号. M23641 CAS No. 1489263-00-4
KI-7 是一种腺苷 A2B 受体正变构调节剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥721 | 有现货 |
![]() ![]() |
10MG | ¥1239 | 有现货 |
![]() ![]() |
25MG | ¥2576 | 有现货 |
![]() ![]() |
50MG | ¥3969 | 有现货 |
![]() ![]() |
100MG | ¥5978 | 有现货 |
![]() ![]() |
500MG | ¥12393 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称KI-7
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述KI-7 是一种腺苷 A2B 受体正变构调节剂。
-
产品描述KI-7 is an adenosine A2B receptor positive allosteric modulator.
-
体外实验KI-7 (1 μM; 5-21 days; mesenchymal stem cells) induces a significant increase in mRNA expression of Runx2 and Osterix.KI-7 (1 μM; 15-21 days) induced a significant increase in cell viability in both differentiation stages.KI-7, as A2B adenosine receptor positive allosteric modulator in MSCs, demonstrating it is able to potentiate the effects of either adenosine and synthetic orthosteric A2B adenosine receptor agonists in mediating osteoblast differentiation in vitro. NECA, BAY 60-6583 and KI-7 induce a strong increase in IL-6 production. KI-7 is able to potentiate the effects of orthosteric agonists in both differentiation stages, even if the effect became significant only at 21 days.
-
体内实验——
-
同义词——
-
通路Apoptosis
-
靶点Adenosine Receptor
-
受体A2B
-
研究领域——
-
适应症——
化学信息
-
CAS Number1489263-00-4
-
分子量354.4
-
分子式C23H18N2O2
-
纯度>98% (HPLC)
-
溶解度DMSO:240 mg/mL?(677.20 mM;?Need ultrasonic)
-
SMILESO=C(C(Nc1ccccc1)=O)c1cn(Cc2ccccc2)c2c1cccc2
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Trincavelli ML, et al. Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta. 2014;1840(3):1194-1203.
产品手册




关联产品
-
Tonapofylline
一种有效的、选择性的、口服生物可利用的腺苷 A1 (A1A) 受体拮抗剂,Ki 为 7 nM。
-
KI-7
KI-7 是一种腺苷 A2B 受体正变构调节剂。
-
BAY 60-6583
BAY 60-6583 (BAY606583) 是一种有效的选择性腺苷 A2B 受体激动剂,EC50 为 2.83 nM。